ABOS — Acumen Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1576885 ·
Last close
$0.23
Market Cap
$16.64M
52W High
$3.60
52W Low
$0.19
ADV30
5,055,869
Next earnings
2026-10-26

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,813,000 -25,369,000 85,565,000 53,075,000 50,955,000
Jun 2026 0 — -32,556,000 -32,718,000 116,007,000 59,443,000 58,744,000
Mar 2026 0 — -21,149,000 -20,737,000 133,629,000 51,796,000 46,153,000
Dec 2025 0 — -25,199,000 -25,138,000 122,833,000 53,989,000 52,403,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-87,952,000
Investing CF
$63,693,000
Financing CF
$30,501,000
CapEx
$-88,000
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.57
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-525,286,000
Inventory
—
Receivables
$1,747,000
ST Investments
$25,529,000
EBIT TTM
$-99,713,000
Pretax Income TTM
$-103,962,000
Interest Exp TTM
$4,249,000
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -123,832,000 -121,335,000 122,833,000 52,403,000 70,430,000 -115,538,000
Dec 2024 0 -114,017,000 -102,329,000 238,992,000 57,176,000 181,816,000 -86,215,000
Dec 2023 0 -61,138,000 -52,371,000 310,125,000 43,152,000 266,973,000 -43,064,000
Dec 2022 0 -45,237,000 -42,856,000 196,587,000 7,812,000 188,775,000 -35,153,000

TTM Snapshot

Revenues TTM
$5,136,000
NetIncome TTM
$-105,044,000
OpCashFlow TTM
—
Assets (Latest)
$116,007,000
Forward EPS
$-0.49

Peers — same industry

TickerNameMarket CapLastDaily %
BSEM BioStem Technologies, Inc. $17.93M $0.94 —
CKDXF Opthea Ltd $14.64M $0.01 —
ESLA Estrella Immunopharma, Inc. $14.42M $0.33 —
PLUR Pluri Inc. $14.09M $0.98 —
PASG Passage BIO, Inc. $13.58M $4.22 —

News headlines (Yahoo Finance, 1h cache)

Alzheimer's families just lost one of their biggest hopes
2026-11-10 00:37 · Yahoo
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
2026-11-05 02:08 · Yahoo
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
2026-10-30 11:00 · Yahoo
Acumen Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-10-26 16:42 · Yahoo
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
2026-10-26 16:12 · Yahoo
Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer’s Data Approach
2026-10-26 14:09 · Yahoo
Acumen Pharmaceuticals Q3 Earnings Call Highlights
2026-10-26 14:02 · Yahoo
Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%
2026-10-26 12:07 · Yahoo
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
2026-10-26 11:00 · Yahoo
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Dis
2026-10-22 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.